PMID- 35021563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220113
IS  - 2576-6422 (Electronic)
IS  - 2576-6422 (Linking)
VI  - 2
IP  - 12
DP  - 2019 Dec 16
TI  - Gold Nanorods Functionalized with Cathepsin B Targeting Peptide and Doxorubicin 
      for Combinatorial Therapy against Multidrug Resistance.
PG  - 5697-5706
LID - 10.1021/acsabm.9b00755 [doi]
AB  - Multidrug resistance (MDR) and adverse effects of chemotherapeutic agents are 
      severe issues in clinical cancer treatment. Due to the dysregulation of enzymes 
      in the cancer cells, enzyme-responsive drug delivery systems (DDSs) have been 
      considered as a viable technology for cancer chemotherapy. In the present work, 
      doxorubicin (DOX) is visible after leaving from AuNR-LAX. After treatment with 
      AuNR-LAX, the drug resistance index of DOX-resistant MCF-7/ADR cells was reduced 
      from extremely high 955.0 to 1.7, implying high potential of AuNR-LAX in the MDR 
      phenotype cancer treatment. In addition, the cellular viability of both MCF-7 and 
      MCF-7/ADR cells decreased from 50% to 80% after treatment with AuNR-LAX along 
      (equivalent DOX concentration = 2.3 mug/mL, Au concentration = 30 mug/mL) to below 
      10% after AuNR-LAX treatment plus radiation of 808 nm, due to the NIR 
      photothermal effect of AuNRs. Human bronchial epithelial cell line 16HBE was 
      chosen to evaluate the adverse effect of AuNR-LAX on the normal cells. At the low 
      concentration, the cytotoxicity of LAX and AuNR-LAX is comparable for breast 
      cancer cell MCF-7 and normal cell 16HBE. It is noted that, at high concentration 
      (with equivalent DOX concentration = 13.1 mug/mL, Au concentration = 167.7 mug/mL), 
      the cellular viability of 16HBE cells is over 50%, whereas that of MCF-7 cancer 
      cells is close to 0, implying the potential of AuNR-LAX in reducing the adverse 
      effects of DOX against normal cells/tissues. Overall, AuNR-LAX showed high 
      potential in overcoming MDR and alleviating adverse effect on normal cells.
FAU - Zhi, Xiaomin
AU  - Zhi X
AD  - School of Pharmaceutics, Capital Medical University, Beijing 100069, China.
FAU - Jiang, Yuqian
AU  - Jiang Y
AD  - School of Pharmaceutics, Capital Medical University, Beijing 100069, China.
FAU - Xie, Linlin
AU  - Xie L
AD  - School of Pharmaceutics, Capital Medical University, Beijing 100069, China.
FAU - Li, Yanbo
AU  - Li Y
AUID- ORCID: 0000-0001-5414-0736
AD  - School of Public Health, Capital Medical University, Beijing 100069, China.
AD  - Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, 
      Beijing 100069, China.
FAU - Fang, Chen-Jie
AU  - Fang CJ
AUID- ORCID: 0000-0003-1450-1271
AD  - School of Pharmaceutics, Capital Medical University, Beijing 100069, China.
LA  - eng
PT  - Journal Article
DEP - 20191112
PL  - United States
TA  - ACS Appl Bio Mater
JT  - ACS applied bio materials
JID - 101729147
SB  - IM
OTO - NOTNLM
OT  - adverse effect
OT  - cathepsin B
OT  - enzyme-responsive release
OT  - gold nanorod
OT  - multidrug resistance
EDAT- 2019/12/16 00:00
MHDA- 2019/12/16 00:01
CRDT- 2022/01/13 01:01
PHST- 2022/01/13 01:01 [entrez]
PHST- 2019/12/16 00:00 [pubmed]
PHST- 2019/12/16 00:01 [medline]
AID - 10.1021/acsabm.9b00755 [doi]
PST - ppublish
SO  - ACS Appl Bio Mater. 2019 Dec 16;2(12):5697-5706. doi: 10.1021/acsabm.9b00755. 
      Epub 2019 Nov 12.